Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina Boni

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Scientific Reports|January 25, 2017
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinibArancha Cebrián, Teresa Gómez Del Pulgar, María José Méndez-Vidal, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Frontiers in Oncology|May 15, 2023
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancerRubén Olivera-Salguero, Elia Seguí, Juan Miguel Cejalvo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
Nature|February 14, 2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Scientific Reports|January 25, 2017
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinibArancha Cebrián, Teresa Gómez Del Pulgar, María José Méndez-Vidal, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Frontiers in Oncology|May 15, 2023
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancerRubén Olivera-Salguero, Elia Seguí, Juan Miguel Cejalvo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
Nature|February 14, 2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Pageof 7